AMINOSYN II 10% W/ ELECTROLYTES
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMINOSYN II 10% W/ ELECTROLYTES (AMINOSYN II 10% W/ ELECTROLYTES).
Amino acids serve as substrates for protein synthesis and nitrogen balance; electrolytes maintain osmotic and acid-base balance.
| Metabolism | Amino acids undergo transamination, deamination, and urea cycle in the liver; electrolytes are regulated by renal excretion. |
| Excretion | Amino acids are primarily metabolized to urea and other nitrogenous waste products, which are excreted renally (90-95% of total nitrogen excreted as urea). Unmetabolized amino acids in plasma are also filtered and reabsorbed by the kidneys; negligible amounts are excreted unchanged (<5%). Biliary/fecal excretion is minimal (<2%). |
| Half-life | The terminal elimination half-life of individual amino acids varies but is generally short (range 0.5–2 hours) due to rapid uptake and metabolism. Clinically, the half-life of infused amino acids is not a relevant parameter for dosing; rather, infusion rate is adjusted to maintain nitrogen balance. |
| Protein binding | Amino acids are highly water-soluble and exhibit minimal protein binding (<10%). Most amino acids are not bound to plasma proteins; exceptions include tryptophan (80-90% bound to albumin) and tyrosine (<10% bound). Binding proteins: albumin (for tryptophan), otherwise negligible. |
| Volume of Distribution | Total amino acids distribute into total body water (Vd approximately 0.45–0.6 L/kg), reflecting their distribution into extracellular and intracellular compartments. The Vd varies for individual amino acids based on polarity and transport; most amino acids have Vd in the range of 0.3–0.7 L/kg. Clinically, this indicates rapid distribution to tissues. |
| Bioavailability | Intravenous: 100%. Not intended for other routes; oral administration is not bioequivalent as first-pass metabolism alters amino acid profile. |
| Onset of Action | Intravenous: Upon initiation of infusion, plasma amino acid levels rise immediately, with clinical effects (e.g., increased nitrogen retention, protein synthesis) detectable within 1–2 hours of continuous administration. |
| Duration of Action | After discontinuation of a short-term infusion, plasma amino acid levels decline rapidly with return to baseline within 2–4 hours. For continuous infusion used for parenteral nutrition, the duration of action is sustained as long as infusion continues; there is no persistent effect beyond the infusion period. |
1-2 g/kg/day (0.1-0.2 g/kg/hour) IV via central line as continuous infusion.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <50 mL/min: reduce dose to 0.5-0.8 g/kg/day and monitor BUN/creatinine. GFR <15 mL/min: contraindicated unless on dialysis. |
| Liver impairment | Child-Pugh B or C: reduce dose by 50% and monitor ammonia levels; avoid in severe hepatic encephalopathy. |
| Pediatric use | Neonates: 2-3 g/kg/day; Infants/Children: 2-2.5 g/kg/day; maximum infusion rate 0.2 g/kg/hour. |
| Geriatric use | Start at lower end of dosing range (0.8-1 g/kg/day) due to decreased renal function; monitor fluid and electrolyte status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN II 10% W/ ELECTROLYTES (AMINOSYN II 10% W/ ELECTROLYTES).
| Breastfeeding | Aminosyn II 10% with Electrolytes is a sterile solution for IV infusion. Amino acids are normal constituents of breast milk. Exogenous amino acids enter the maternal circulation and may be secreted into milk, but the impact on nursing infants is unknown. No data on M/P ratio are available. Use with caution in breastfeeding women, weighing benefits against potential risks. |
| Teratogenic Risk | No known teratogenic risk profile; data are scant. However, high-dose amino acid infusion during pregnancy may be associated with maternal metabolic acidosis or electrolyte disturbances that could theoretically affect fetal acid-base balance. Trimester-specific risks are not well documented. Use only if clearly needed. |
■ FDA Black Box Warning
This product contains aluminum that may reach toxic levels with prolonged parenteral administration in patients with impaired renal function.
| Serious Effects |
Severe electrolyte disturbances, anuria, inborn errors of amino acid metabolism, hypersensitivity to any component
| Precautions | Monitor for fluid and electrolyte imbalances, hyperammonemia, and renal function; use caution in patients with hepatic or renal impairment. |
| Food/Dietary | No direct food interactions as this is an intravenous solution. However, if transitioning to oral intake, avoid high-protein meals if renal function is compromised. Maintain adequate hydration. Consider total caloric intake when combining with enteral nutrition. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolyte levels, acid-base status, blood glucose, and plasma amino acid profiles. Observe for signs of hyperammonemia, azotemia, and metabolic acidosis. Fetal monitoring should include assessment of fetal growth and well-being via ultrasound, especially if maternal metabolic derangements occur. |
| Fertility Effects | No known effects on fertility. The product is a nutritional supplement and not known to impair reproductive function in humans. |
| Clinical Pearls | Aminosyn II 10% with Electrolytes is a crystalline amino acid solution used for parenteral nutrition; ensure gradual initiation to avoid hyperglycemia; monitor serum electrolytes, BUN, and ammonia regularly; avoid rapid infusion rates to prevent metabolic acidosis; do not use as a protein substitute in patients with hepatic encephalopathy; consider adding lipid emulsion for energy balance; check compatibility with other IV additives before mixing. |
| Patient Advice | This medication is used to provide nutrition when you cannot eat by mouth. · It will be given through a central or peripheral vein as part of total parenteral nutrition (TPN). · Report any signs of infection at the IV site, such as redness, swelling, or pain. · Inform your healthcare provider if you experience rapid breathing, confusion, or unusual fatigue. · Regular blood tests will be needed to monitor your electrolyte levels and kidney function. · Do not adjust the infusion rate yourself; the rate is carefully calculated for your needs. |